Heart failure & cardiomyopathies
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial
Primary resultResult — go to the resultHazard ratio 0.86 95% CI 0.75–1.00Authors' conclusion
In this post hoc analysis of the GALACTIC-HF trial, we observed a potential reduction in life-threatening arrhythmia, cardiac arrest, and SD with OM treatment, especially in patients with severely reduced LVEF.
Study context
- Population
- Symptomatic chronic HF with LVEF ≤35%
- Participants
- 8,232 participants
- Comparison
- Omecamtiv mecarbil vs placebo
- Primary endpoint
- Composite of:
- First serious VA
- Cardiac arrest
- SD
- Follow-up
- Median 21.8 months
Methodological detailspost hoc analysis, placebo-controlled, ventricular arrhythmias (VA) and cardiac arrest investigator-reported adverse events; SD centrally adjudicated
- Post hoc analysis
- Placebo-controlled
- VA and cardiac arrest investigator-reported adverse events; SD centrally adjudicated
Primary result
As reported in the abstract
Hazard ratio
0.86
95% CI 0.75–1.00
P = 0.054
Events by treatment group
Placebo
377
events
Omecamtiv mecarbil (OM)
329
events
OMvs Placebo
HR 0.86 (95% CI 0.75–1.00); P = 0.054
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Composite arrhythmic outcome, LVEF ≤ median 28% (subgroup) | 0.77 (0.63–0.94) | P = 0.009 | |
| 0.512Hazard ratio (log scale) |
Composite arrhythmic outcome, severe HF (subgroup)
- Association appeared consistent in severe HF
Original publication
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial. Eur J Heart Fail. Published 12 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →